Following its acquisition of Salix Pharmaceuticals in 2015,
Valeant entered a new therapeutic area, gastrointestinal disorders.
The gastrointestinal (GI) segment is a growing specialty
market with significant unmet needs, many of which are chronic, can be damaging
to the quality of life and are often undertreated. Among Salix’s key products
are Xifaxan® 550 mg (indicated for irritable bowel syndrome with diarrhea and
hepatic encephalopathy), Xifaxan 200 mg (traveler’s diarrhea), Relistor®
(opioid-induced constipation), and Uceris® and Apriso® (ulcerative colitis).
Other GI products include Ruconest®, Giazo®, Moviprep®,
Osmoprep®, Solesta®, Fulyzaq®, Deflux®, Glumetza®, Cycloset® and Zegerid®.
With an expanded sales force and a greater focus on
direct-to-consumer and patient engagement marketing, Valeant is committed to
providing healthcare professionals and patients the most effective solutions in